Gland Pharma Limited has informed the Exchange regarding a press release dated March 04, 2026, titled "Gland Pharma Receives Tentative Approval for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC)".
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma has received tentative approval from the USFDA for its generic version of Brimonidine Tartrate Ophthalmic Solution 0.025%, an over-the-counter eye drop used to relieve eye redness. The product is a generic equivalent of Bausch & Lomb's Lumify brand. According to IQVIA, the reference product had US sales of about USD 39 million in the 12 months ending September 2025. Gland Pharma is a Hyderabad-based generic injectable and ophthalmic-focused company with presence in 60 countries. The tentative approval means Gland is cleared to launch the product in the US once any patent or exclusivity barriers on the original drug expire.
Mildly positive for the stock — it strengthens Gland's US ophthalmic pipeline and opens a potential revenue stream in a USD 39 million US market, though tentative approval means actual sales can only begin after patent hurdles clear.